SUVEN LIFE SCIENCES | CIPLA | SUVEN LIFE SCIENCES/ CIPLA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -81.5 | 32.7 | - | View Chart |
P/BV | x | 1.3 | 4.6 | 27.7% | View Chart |
Dividend Yield | % | 1.8 | 0.4 | 405.3% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUVEN LIFE SCIENCES Mar-19 |
CIPLA Mar-20 |
SUVEN LIFE SCIENCES/ CIPLA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 338 | 586 | 57.7% | |
Low | Rs | 169 | 357 | 47.5% | |
Sales per share (Unadj.) | Rs | 52.1 | 207.0 | 25.2% | |
Earnings per share (Unadj.) | Rs | 6.8 | 18.6 | 36.7% | |
Cash flow per share (Unadj.) | Rs | 8.6 | 33.2 | 25.8% | |
Dividends per share (Unadj.) | Rs | 1.50 | 4.00 | 37.5% | |
Dividend yield (eoy) | % | 0.6 | 0.8 | 69.7% | |
Book value per share (Unadj.) | Rs | 65.3 | 195.5 | 33.4% | |
Shares outstanding (eoy) | m | 127.28 | 806.35 | 15.8% | |
Bonus/Rights/Conversions | - | ESOS | - | ||
Price / Sales ratio | x | 4.9 | 2.3 | 213.7% | |
Avg P/E ratio | x | 37.1 | 25.3 | 146.5% | |
P/CF ratio (eoy) | x | 29.6 | 14.2 | 208.2% | |
Price / Book Value ratio | x | 3.9 | 2.4 | 161.1% | |
Dividend payout | % | 22.0 | 21.5 | 102.1% | |
Avg Mkt Cap | Rs m | 32,272 | 379,912 | 8.5% | |
No. of employees | `000 | 1.1 | 25.8 | 4.2% | |
Total wages/salary | Rs m | 661 | 30,270 | 2.2% | |
Avg. sales/employee | Rs Th | 6,132.2 | 6,459.6 | 94.9% | |
Avg. wages/employee | Rs Th | 611.1 | 1,171.2 | 52.2% | |
Avg. net profit/employee | Rs Th | 803.5 | 580.2 | 138.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,635 | 166,949 | 4.0% | |
Other income | Rs m | 242 | 3,442 | 7.0% | |
Total revenues | Rs m | 6,877 | 170,391 | 4.0% | |
Gross profit | Rs m | 1,604 | 32,060 | 5.0% | |
Depreciation | Rs m | 221 | 11,747 | 1.9% | |
Interest | Rs m | 38 | 1,974 | 1.9% | |
Profit before tax | Rs m | 1,587 | 21,782 | 7.3% | |
Minority Interest | Rs m | 0 | -475 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 718 | 6,312 | 11.4% | |
Profit after tax | Rs m | 869 | 14,995 | 5.8% | |
Gross profit margin | % | 24.2 | 19.2 | 125.9% | |
Effective tax rate | % | 45.2 | 29.0 | 156.1% | |
Net profit margin | % | 13.1 | 9.0 | 145.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,232 | 117,038 | 5.3% | |
Current liabilities | Rs m | 1,490 | 43,931 | 3.4% | |
Net working cap to sales | % | 71.5 | 43.8 | 163.2% | |
Current ratio | x | 4.2 | 2.7 | 157.0% | |
Inventory Days | Days | 86 | 96 | 90.3% | |
Debtors Days | Days | 83 | 85 | 97.1% | |
Net fixed assets | Rs m | 4,043 | 107,424 | 3.8% | |
Share capital | Rs m | 127 | 1,613 | 7.9% | |
"Free" reserves | Rs m | 8,183 | 156,018 | 5.2% | |
Net worth | Rs m | 8,310 | 157,630 | 5.3% | |
Long term debt | Rs m | 18 | 23,693 | 0.1% | |
Total assets | Rs m | 10,389 | 236,626 | 4.4% | |
Interest coverage | x | 43.1 | 12.0 | 358.1% | |
Debt to equity ratio | x | 0 | 0.2 | 1.4% | |
Sales to assets ratio | x | 0.6 | 0.7 | 90.5% | |
Return on assets | % | 8.7 | 7.2 | 121.8% | |
Return on equity | % | 10.5 | 9.5 | 110.0% | |
Return on capital | % | 19.5 | 12.8 | 152.0% | |
Exports to sales | % | 0 | 33.0 | 0.0% | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | 55,175 | 0.0% | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 5,622 | 56,036 | 10.0% | |
Fx outflow | Rs m | 1,799 | 6,764 | 26.6% | |
Net fx | Rs m | 3,822 | 49,272 | 7.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 356 | 30,685 | 1.2% | |
From Investments | Rs m | -279 | 1,040 | -26.8% | |
From Financial Activity | Rs m | -225 | -29,488 | 0.8% | |
Net Cashflow | Rs m | -148 | 2,340 | -6.3% |
Indian Promoters | % | 63.4 | 16.0 | 396.3% | |
Foreign collaborators | % | 0.0 | 20.8 | - | |
Indian inst/Mut Fund | % | 0.0 | 12.2 | - | |
FIIs | % | 0.0 | 23.7 | - | |
ADR/GDR | % | 0.0 | 1.1 | - | |
Free float | % | 36.5 | 26.2 | 139.3% | |
Shareholders | 37,287 | 161,166 | 23.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare SUVEN LIFE SCIENCES With: JUBILANT PHARMOVA DR. DATSONS LABS CADILA HEALTHCARE GSK PHARMA PANACEA BIOTECH
Compare SUVEN LIFE SCIENCES With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets crashed yesterday as fears that the government could go for stricter lockdowns to curb the second wave of Covid-19.
For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsA tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
What should you do if the market falls? In this video, I'll tell you what I will do.
More